<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00541840</url>
  </required_header>
  <id_info>
    <org_study_id>GEIS01-07</org_study_id>
    <nct_id>NCT00541840</nct_id>
  </id_info>
  <brief_title>Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma</brief_title>
  <official_title>Phase I-II, Not-Randomized, Multicenter Clinical Trial to Evaluate Safety and Efficacy of Sorafenib (BAY-43-9006) in Combination With Ifosfamide in Soft Tissue Sarcoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Investigacion en Sarcomas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol de Investigacion en Sarcomas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Soft tissue sarcomas (STS) are an uncommon group of malignant tumors of mesenchymal origin.&#xD;
      For most advanced STS types, chemotherapy is currently the only available treatment.&#xD;
      Unfortunately, a very limited number of useful drugs are active against this disease.&#xD;
      Doxorubicin is widely considered the standard first-line treatment. Ifosfamide has also a&#xD;
      well-established activity (1,2) and is often administered either associated with Doxorubicin&#xD;
      or alone as a second-line chemotherapy treatment. Other drugs such as DTIC, Gemcitabine and&#xD;
      Temozolomide showed modest activity as a second-line agents (3,4). Thus, there is a necessity&#xD;
      to identify new agents with activity to improve therapy for patients with advanced STS. In&#xD;
      some studies, most STS showed VEGF expression, and elevated serum VEGF levels were found to&#xD;
      correlate with higher histologic tumor grade (5,6). Additionally, inhibition of VEGFR was&#xD;
      associated with tumor activity in preclinical models of sarcoma (7,8). For these reasons,&#xD;
      inhibition of VEGFR seems to be a reasonable approach to explore in the treatment of STS.&#xD;
      Sorafenib (BAY 43-9006) is an orally available, small molecule multi-kinase inhibitor of&#xD;
      VEGFR, PDGFR and RAF with demonstrated activity in the treatment of renal cell cancer (9).&#xD;
      Preclinical studies suggest that the combination of Sorafenib with cytotoxic agents results&#xD;
      in additive anti-tumor activity (10), initiating justification for combination studies. A&#xD;
      recent trial, however, reported an unexpected incidence of cardiac toxicity in patients with&#xD;
      STS treated with Bevacizumab, a monoclonal antibody that binds VEGF, in combination with&#xD;
      Doxorubicin (11). This finding suggest that the possibility of potentiation of the&#xD;
      cardiotoxicity of Doxorubicin when inhibiting the VEGF pathway cannot be ruled out. The&#xD;
      association of Sorafenib with Ifosfamide, the other established active agent against STS,&#xD;
      could improve the efficacy of single-agent Ifosfamide minimizing the risk of cardiac toxicity&#xD;
      .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">April 2010</completion_date>
  <primary_completion_date type="Anticipated">April 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Safety profile and to determine maximum tolerated dose (MTD) / Recommended Dose (DR) of Sorafenib in combination with Ifosfamide. Phase II: Activity profile evaluating of the combination in patients with advanced soft tissue sarcoma.</measure>
    <time_frame>Phase II: Progression free rate: at 3 and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II: Efficacy evaluation</measure>
    <time_frame>Phase II: Progression free rate at 3 and 6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Phase I:&#xD;
Level 1: Sorafenib 200 mg bid, orally Ifosfamide 2,0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration&#xD;
Level 2: Sorafenib 400 mg bid, orally Ifosfamide 2.00 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration&#xD;
Level 3 : Sorafenib 400mg bid, orally Ifosfamide 2.5 g/m2 , intravenously , over 4 hours , on 3 consecutive days . Mesna 500mg/m2,iv,at 0,4 and 8 hours after ifosfamide administration .&#xD;
Level 4 : Sorafenib 400 mg bid, orally Ifosfamide 3.0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 600 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration&#xD;
Phase II:&#xD;
Sorafenib and Ifosfamide administered at the doses recommended in phase I until progression or unacceptable toxicity.</description>
    <other_name>BAY 43-9006</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Advanced Soft Tissue Sarcoma histologically proven, excluding the following subtypes:&#xD;
             chondrosarcoma, osteosarcoma, Ewing's sarcoma, and embryonal rhabdomyosarcoma.&#xD;
&#xD;
          2. Patients must have been previously treated with Anthracycline. However, patients not&#xD;
             eligible for Anthracycline treatment can be included.Prior treatment with Ifosfamide&#xD;
             is not allowed, except if it was administered as adjuvant therapy.&#xD;
&#xD;
          3. Patients must be &gt; 18 and &lt; 72 years old.&#xD;
&#xD;
          4. Patients must have ECOG performance status 0 to 1 on fase I.&#xD;
&#xD;
          5. Patients must have ECOG performance status 0 to 2 on fase II.&#xD;
&#xD;
          6. Patients must have measurable disease. Progression must be documented during the last&#xD;
             month pre-study entry. No prior radiotherapy in the indicator lesion is allowed.&#xD;
&#xD;
          7. Adequate bone marrow, renal and hepatic function&#xD;
&#xD;
               -  hemoglobin ³ 9.0 g/dl&#xD;
&#xD;
               -  absolute neutrophil count ³ 1,500/mm3&#xD;
&#xD;
               -  platelet count ³ 100,000/mm3&#xD;
&#xD;
               -  total bilirubin £ 1.5 times the upper limit of normal&#xD;
&#xD;
               -  ALT and AST £ 2.5 times the upper limit of normal (£ 5 x upper limit of normal&#xD;
                  for patients with liver involvement)&#xD;
&#xD;
               -  INR £ 1.5 and aPTT within normal limits&#xD;
&#xD;
               -  serum creatinine £ 1.5 the upper limit of normal&#xD;
&#xD;
          8. Signed informed consent prior to any study specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with previous chemotherapy or radiotherapy, within 3 weeks prior to study&#xD;
             entry.&#xD;
&#xD;
          2. Pregnant or breast feeding patients. Women of childbearing potential must have a&#xD;
             negative pregnancy test performed within 7 days prior to the start of treatment. Both&#xD;
             men and women enrolled in this trial must use adequate barrier birth control measures&#xD;
             during the course of the trial.&#xD;
&#xD;
          3. Life expectancy of less than 12 weeks.&#xD;
&#xD;
          4. General medical or psychological conditions that would preclude appropriate informed&#xD;
             consent or compliance with the protocol.&#xD;
&#xD;
          5. Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the patients participation in the study.&#xD;
&#xD;
          6. Previous cancer that is distinct in primary site or histology from NSCLC except&#xD;
             cervical cancer in-situ, treated basal cell carcinoma, superficial bladder tumors (Ta&#xD;
             and Tis) or any cancer curatively treated &gt; 3 years prior to study entry.&#xD;
&#xD;
          7. Concurrent treatment with other anti-cancer therapy.&#xD;
&#xD;
          8. Concurrent treatment with other experimental drugs (within 30 days prior to study&#xD;
             entry).&#xD;
&#xD;
          9. Significant weight loss (&gt; or equal 10% body weight during preceding 6 weeks).&#xD;
&#xD;
         10. Major surgery, open biopsy or significant traumatic injury within 4 weeks of first&#xD;
             dose of study drug.&#xD;
&#xD;
         11. Biological modifying agents such as G-CSF administered within 3 weeks prior to study&#xD;
             entry.&#xD;
&#xD;
         12. Known or suspected allergy to sorafenib or ifosfamide.&#xD;
&#xD;
         13. Evidence or history of bleeding diathesis or coagulopathy.&#xD;
&#xD;
         14. Therapeutic anticoagulation with Vitamin K antagonists such as warfarin or with&#xD;
             heparins or heparinoids. Low dose warfarin is permitted if INR is &lt;1.5. Low dose&#xD;
             aspirin is permitted.&#xD;
&#xD;
         15. Thrombotic or embolic events such as cerebrovascular accident including transient&#xD;
             ischemic attacks within the past 6 months.&#xD;
&#xD;
         16. Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mm Hg or diastolic&#xD;
             pressure &gt; 90 mm Hg, despite optimal medical management.&#xD;
&#xD;
         17. Cardiac disease: Congestive heart failure &gt; class II NYHA. Patients must not have&#xD;
             unstable angina or new-onset angina (began within the last 3 months) or myocardial&#xD;
             infarction within the last 6 months.&#xD;
&#xD;
         18. Active clinically serious infections &gt; CTCAE Grade 2.&#xD;
&#xD;
         19. Serious, non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
         20. Concomitant treatment with ketoconazole, itraconazole, ritonavir, rifampicin and St.&#xD;
             John´s Wort.&#xD;
&#xD;
         21. Known HIV infection or chronic hepatitis B or C.&#xD;
&#xD;
         22. Known brain metastasis. Patients with neurological symptoms should undergo a CT&#xD;
             scan/MRI of the brain to exclude brain metastasis.&#xD;
&#xD;
         23. Any other condition that could compromise patient's security and/or study's&#xD;
             fulfilment.&#xD;
&#xD;
         24. Known or suspected allergy to mesna or tiolic agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Garcia del Muro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Grupo Español de Investigacion en Sarcomas (GEIS)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xavier Garcia del Muro, MD</last_name>
    <phone>93 260 73 32</phone>
    <email>garciadelmuro@ico.scs.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Grupo Geis</name>
      <address>
        <city>Madrid</city>
        <zip>28001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Garcia del Muro, MD</last_name>
      <phone>915775281</phone>
      <email>info@grupogeis.org</email>
    </contact>
    <investigator>
      <last_name>Xavier Garcia del Muro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.grupogeis.org/</url>
    <description>Grupo Español de Investigacion en Sarcomas Website</description>
  </link>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>October 9, 2007</study_first_submitted>
  <study_first_submitted_qc>October 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2007</study_first_posted>
  <last_update_submitted>May 8, 2008</last_update_submitted>
  <last_update_submitted_qc>May 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Grupo Espanol de Investigacion en Sarcoma</name_title>
    <organization>Grupo GEIS</organization>
  </responsible_party>
  <keyword>Sarcoma</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>GEIS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

